From Seekingalpha · Derek Lowe · · 50s
Merck Moderna Melanoma Therapy Shows 42% Lower Recurrence Risk
Merck and Moderna's melanoma combo therapy cuts recurrence risk by 42% in Phase 3 trial.
In brief
Merck and Moderna's melanoma combo therapy cuts recurrence risk by 42% in Phase 3 trial. Merck and Moderna's melanoma combination therapy reduced recurrence or death risk by 42% after two years of follow-up in Phase 3 trial. Originally reported by Seekingalpha.
Merck and Moderna Release Melanoma Trial Data
Merck and Moderna released clinical trial data on October 22, 2026 for their vaccine (intismeran autogene)/Keytruda combination in melanoma patients after surgery.
Phase III Trial Shows 42% Lower Recurrence Risk
The Phase III data announced yesterday showed a 42% reduction in the risk of death or recurrence of melanoma after a median follow-up of two years.
Combination Therapy Outperforms Keytruda Alone
After two years, 82.2% of the combination treatment group had not relapsed versus 70% of Keytruda-alone patients.
The short version
Merck and Moderna's melanoma combination therapy reduced recurrence or death risk by 42% after two years of follow-up in Phase 3 trial.
